The Search for Viral Eradication

Hepatitis C in Renal Disease, Hemodialysis and Transplantation

This flow follows the therapeutic progression from interferon monotherapy toward combination treatment and the first direct-acting antiviral regimens.

increasing

Bearing strength in each event

decreasing

Interferon Monotherapy Interferon Monotherapy from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Interferon Monotherapy

Interferon Monotherapy

Combination Breakthrough Combination Breakthrough from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Combination Breakthrough

Combination Breakthrough

Direct Acting Antivirals Direct Acting Antivirals from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Direct Acting Antivirals A new therapeutic class Direct-acting antiviral drugs targeted viral protease and polymerase mechanisms rather than relying solely on…

Direct Acting Antivirals from "Hepatitis C in Renal Disease, Hemodialysis and Transplantation". Direct Acting Antivirals A new therapeutic class Direct-acting antiviral drugs targeted viral protease and polymerase mechanisms rather than relying solely on…

Direct Acting Antivirals A new therapeutic class Direct-acting antiviral drugs targeted viral protease and polymerase mechanisms rather than relying solely on immune stimulation. Approval of telaprevir and boceprevir raised response rates for difficult genotype 1 infection. New limitations The advance shifted the conflict toward anemia, rash, drug interactions, resistance, cost, and adherence. Cure became more attainable, but treatment still required careful clinical orchestration.

early 1990s

late 1990s to early 2000s

2011 approval period